Aquestive Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Aquestive Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2017 to Q2 2024.
  • Aquestive Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$2.75M, a 52.6% increase year-over-year.
  • Aquestive Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$25.7M, a 13.7% decline year-over-year.
  • Aquestive Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$7.87M, a 85.5% increase from 2022.
  • Aquestive Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$54.4M, a 22.9% increase from 2021.
  • Aquestive Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$70.5M, a 26.5% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$25.7M -$2.75M +$3.05M +52.6% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$28.8M -$12.8M -$20.9M -259% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-06
Q4 2023 -$7.87M -$8.11M +$4.24M +34.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-05
Q3 2023 -$12.1M -$2.04M +$10.5M +83.8% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-06
Q2 2023 -$22.6M -$5.79M +$10.5M +64.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$33.1M $8.07M +$21.3M Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-06
Q4 2022 -$54.4M -$12.4M +$16.6M +57.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-05
Q3 2022 -$71M -$12.5M +$2.02M +13.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 -$73M -$16.3M -$3.94M -31.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-06
Q1 2022 -$69.1M -$13.2M +$1.45M +9.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-06
Q4 2021 -$70.5M -$28.9M -$8.58M -42.1% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$62M -$14.6M +$2M +12.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 -$64M -$12.4M -$10M -430% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-01
Q1 2021 -$53.9M -$14.7M +$1.86M +11.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-01
Q4 2020 -$55.8M -$20.4M -$7.73M -61.2% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-09
Q3 2020 -$48.1M -$16.6M +$1.86M +10.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-02
Q2 2020 -$49.9M -$2.33M +$18.1M +88.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-02
Q1 2020 -$68.1M -$16.5M -$1.8M -12.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-02
Q4 2019 -$66.2M -$12.6M +$1.31M +9.38% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-09
Q3 2019 -$67.6M -$18.4M -$3.37M -22.4% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-09
Q2 2019 -$64.2M -$20.5M +$16M +43.9% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-09
Q1 2019 -$80.2M -$14.7M -$18.8M -459% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-09
Q4 2018 -$61.4M -$13.9M -$3.9M -38.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-11
Q3 2018 -$57.5M -$15M -$23.5M -278% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-11
Q2 2018 -$34M -$36.5M -$30.6M -519% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-11
Q1 2018 -$3.39M $4.1M +$5.56M Jan 1, 2018 Mar 31, 2018 10-K 2020-03-11
Q4 2017 -$8.94M -$10M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-14
Q3 2017 $8.45M Jul 1, 2017 Sep 30, 2017 10-K 2019-03-14
Q2 2017 -$5.9M Apr 1, 2017 Jun 30, 2017 10-K 2019-03-14
Q1 2017 -$1.46M Jan 1, 2017 Mar 31, 2017 10-K 2019-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.